To conclude, we uncovered that melatonin suppressed glycolysis to inhibit the tumorigenesis of BLCA and identified that the PPARγ-ENO1 axis was the downstream effector of melatonin (Fig. 7). The gene discussed is PPARG; the disease is bladder transitional cell carcinoma.